Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9068591 | 0.80 | MEN1 (0.36) | HSD11B1ALDH1A1LMNAADORA3 | |
| SCHEMBL1896319 | 0.68 | MEN1 (0.40) | POLBEPHX2HSD11B1ALDH1A1LMNA | |
| SCHEMBL206785 | 0.65 | MEN1 (0.49) | POLBEPHX2HSD11B1ALDH1A1LMNA | |
| SCHEMBL6639799 | 0.64 | HSD11B1 (0.35) | POLBEPHX2HSD11B1ALDH1A1ADORA3 | |
| SCHEMBL4500488 | 0.64 | MEN1 (0.44) | POLBEPHX2HSD11B1LMNAADORA3 | |
| SCHEMBL4518124 | 0.63 | MEN1 (0.42) | POLBEPHX2HSD11B1LMNAADORA3 | |
| SCHEMBL14992796 | 0.63 | ALDH1A1 (0.38) | POLBEPHX2HSD11B1ALDH1A1ADORA3 | |
| SCHEMBL7358160 | 0.62 | ALDH1A1 (0.50) | POLBEPHX2HSD11B1ALDH1A1ADORA3 | |
| SCHEMBL26605404 | 0.62 | ALDH1A1 (0.50) | POLBEPHX2HSD11B1ALDH1A1ADORA3 | |
| SCHEMBL26605861 | 0.62 | ALDH1A1 (0.50) | POLBEPHX2HSD11B1ALDH1A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | APEX1 1627/4885BLM 4217/4885POLB 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.